{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:41:43Z","timestamp":1793716903039,"version":"4.6.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Degree & Postgraduate Education Reform Project of Central South University","award":["2023JGB123"],"award-info":[{"award-number":["2023JGB123"]}]},{"name":"Degree & Postgraduate Education Reform Project of Central South University","award":["2024JGB061"],"award-info":[{"award-number":["2024JGB061"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Omadacycline, a novel aminomethylcycline antibiotic for community-acquired bacterial infections, lacks comprehensive real-world safety data. We evaluated its adverse drug reactions (ADRs) using the FDA Adverse Event Reporting System (FAERS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive analysis of post-marketing ADR reports submitted to FAERS between the first quarter of 2020 and the fourth quarter of 2024 was conducted. Disproportionality signals were assessed via four methods: reporting odds ratio (ROR), proportional reporting ratio, Bayesian confidence propagation neural network and multi-item gamma Poisson shrinker.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and conclusion<\/jats:title>\n                    <jats:p>Among 4541 omadacycline-related reports, 577 distinct ADRs were identified. The most frequently reported ADRs were nausea (221 cases, 14.1%), vomiting (129), diarrhoea (93), dyspnoea (56) and rash (52). The strongest safety signals (ROR) included tooth discolouration (ROR\u200a=\u200a184.33, 95% CI\u200a=\u200a96.79\u2013351.06), tongue discolouration (159.88, 101.76\u2013251.25) and Mycobacterium avium complex infection (73.30, 40.15\u2013133.78). Hepatic events (e.g. elevated transaminases) and mortality (49 cases) also demonstrated significant signals. Omadacycline is associated with gastrointestinal disturbances, dental discolouration and respiratory complications. Vigilance for hepatic injury and mortality is warranted, especially in elderly comorbid patients. Ongoing pharmacovigilance integrating real-world evidence is essential.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag006","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T12:45:38Z","timestamp":1767789938000},"source":"Crossref","is-referenced-by-count":27,"title":["A disproportionality analysis of adverse events associated with omadacycline based on the FDA adverse event reporting system database"],"prefix":"10.1093","volume":"81","author":[{"given":"Ye-Lei","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Second Xiangya Hospital, Central South University , Changsha 410011 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Xiangya Hospital, Central South University , Changsha 410078 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ming","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Xiangya Hospital, Central South University , Changsha 410011 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Tao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Xiangya Hospital, Central South University , Changsha 410011 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6694-2450","authenticated-orcid":false,"given":"Jian","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Second Xiangya Hospital, Central South University , Changsha 410011 ,","place":["China"]},{"name":"Hunan Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University , Changsha 410219 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"2026012402562517200_dkag006-B1","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3390\/biom14070783","article-title":"Third-generation tetracyclines: current knowledge and therapeutic potential","volume":"14","author":"Kounatidis","year":"2024","journal-title":"Biomolecules"},{"key":"2026012402562517200_dkag006-B2","doi-asserted-by":"publisher","first-page":"682682","DOI":"10.3389\/fmicb.2021.682682","article-title":"A complementary mechanism of bacterial mRNA translation inhibition by tetracyclines","volume":"12","author":"Barrenechea","year":"2021","journal-title":"Front Microbiol"},{"key":"2026012402562517200_dkag006-B3","doi-asserted-by":"publisher","first-page":"e0323822","DOI":"10.1128\/spectrum.03238-22","article-title":"In vitro antimicrobial activities of tigecycline, eravacycline, omadacycline, and sarecycline against rapidly growing mycobacteria","volume":"11","author":"Zhang","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2026012402562517200_dkag006-B4","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1186\/s12879-024-09983-w","article-title":"Possible omadacycline induce acute pancreatitis: a case report and literature review","volume":"24","author":"Xu","year":"2024","journal-title":"BMC Infect Dis"},{"key":"2026012402562517200_dkag006-B5","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1007\/s40121-024-01065-3","article-title":"Omadacycline for diverse infections in China: a real-world analysis of efficacy and safety","volume":"13","author":"Gao","year":"2024","journal-title":"Infect Dis Ther"},{"key":"2026012402562517200_dkag006-B6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.clinthera.2024.06.014","article-title":"Physiologically based pharmacokinetic model for predicting omadacycline pharmacokinetics and pharmacodynamics in healthy and hepatic impairment populations","volume":"46","author":"Zhang","year":"2024","journal-title":"Clin Ther"},{"key":"2026012402562517200_dkag006-B7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00403-025-03959-9","article-title":"A pharmacovigilance analysis of abrocitinib-related skin adverse events based on the FDA Adverse Event Reporting System (FAERS)","volume":"317","author":"Huang","year":"2025","journal-title":"Arch Dermatol Res"},{"key":"2026012402562517200_dkag006-B8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"2026012402562517200_dkag006-B9","doi-asserted-by":"publisher","first-page":"1558868","DOI":"10.3389\/fphar.2025.1558868","article-title":"A real-world pharmacovigilance analysis of omadacycline in FDA adverse event reporting system (FAERS) database","volume":"16","author":"Shi","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026012402562517200_dkag006-B10","doi-asserted-by":"publisher","first-page":"e14588","DOI":"10.1111\/aas.14588","article-title":"Adverse event signal analysis of remimazolam using the FDA adverse event reporting system database","volume":"69","author":"Liu","year":"2025","journal-title":"Acta Anaesthesiol Scand"},{"key":"2026012402562517200_dkag006-B11","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/pds.5624","article-title":"Sensitivity and specificity in signal detection with the reporting odds ratio and the information component","volume":"32","author":"Trillenberg","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026012402562517200_dkag006-B12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026012402562517200_dkag006-B13","doi-asserted-by":"publisher","first-page":"1524702","DOI":"10.3389\/fphar.2025.1524702","article-title":"Data mining and safety analysis of voriconazole in patients with a hematological malignant tumor based on the FAERS database: differences between children and adults","volume":"16","author":"Li","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026012402562517200_dkag006-B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2025.2467815","article-title":"The efficacy and safety of omadacycline in treating acute bacterial infections: a meta-analysis of randomized controlled trials","author":"Chen","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"2026012402562517200_dkag006-B15","doi-asserted-by":"publisher","first-page":"116711","DOI":"10.1016\/j.diagmicrobio.2025.116711","article-title":"Surveillance of omadacycline against 35,000 bacterial clinical isolates from the United States (2019\u20132023)","volume":"111","author":"Huband","year":"2025","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026012402562517200_dkag006-B16","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3390\/antibiotics12040761","article-title":"Novel antimicrobial agents for gram-negative pathogens","volume":"12","author":"Karvouniaris","year":"2023","journal-title":"Antibiotics"},{"key":"2026012402562517200_dkag006-B17","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1093\/cid\/ciz398","article-title":"An integrated safety summary of omadacycline, a novel aminomethylcycline antibiotic","volume":"69","author":"Opal","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026012402562517200_dkag006-B18","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1080\/14740338.2024.2392865","article-title":"Systematic analysis of the adverse effects of commonly used clinical tetracycline drugs based on the FAERS database","volume":"24","author":"Xiong","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"2026012402562517200_dkag006-B19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/infdis\/jiad537","article-title":"Fecal pharmacokinetics and gut microbiome effects of oral omadacycline versus vancomycin in healthy volunteers","volume":"229","author":"Jo","year":"2024","journal-title":"J Infect Dis"},{"key":"2026012402562517200_dkag006-B20","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12879-023-08212-0","article-title":"Omadacycline for treatment of acute bacterial infections: a meta-analysis of phase II\/III trials","volume":"23","author":"Lin","year":"2023","journal-title":"BMC Infect Dis"},{"key":"2026012402562517200_dkag006-B21","doi-asserted-by":"publisher","first-page":"e0082423","DOI":"10.1128\/aac.00824-23","article-title":"Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes","volume":"67","author":"El Ghali","year":"2023","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkag006\/66561574\/dkag006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkag006\/66561574\/dkag006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T07:56:36Z","timestamp":1769241396000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag006\/8439861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,19]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag006","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,19]]},"article-number":"dkag006"}}